Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT@XBP1
- Development stage
- Preclinical
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FT@XBP1 is a nanoparticle-based siRNA delivery system that targets macrophage-specific *Xbp1* deficiency. The formulation uses folic acid-modified D-α-tocopheryl polyethylene glycol 1000 succinate (FA-TPGS) nanoparticles to deliver siRNA against X-box binding protein 1 (XBP1) to hepatic macrophages, thereby inhibiting XBP1 expression. This targeted silencing shifts macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, reduces pro-inflammatory factor release, and alleviates hepatic steatosis, liver injury, and fibrosis. Its primary experimental indication is metabolic dysfunction-associated steatohepatitis (MASH)[1].
- Brand names
- FT@XBP1
- Other names
- FT + XBP1
02
Targets
XBP1 (X-box-binding protein 1)
Beyond the preview
Go deeper on FT@XBP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT@XBP1.